Marxa L. Figueiredo

Emerging patent landscape for non-viral vectors used for gene therapy

Nature Biotechnology · 2020-02-01 · 86 citations

Advances in the Development and the Applications of Nonviral, Episomal Vectors for Gene Therapy

Human Gene Therapy · 2021-08-05 · 34 citations

Nonviral and nonintegrating episomal vectors are reemerging as a valid, alternative technology to integrating viral vectors for gene therapy, due to their more favorable safety profile, significantly lower risk for insertional mutagenesis, and a lesser potential for innate immune reactions, in addition to their low production cost. Over the past few years, attempts have been made to generate highly functional nonviral vectors that display long-term maintenance within cells and promote more susta…

Granular Hydrogels Improve Myogenic Invasion and Repair after Volumetric Muscle Loss

Advanced Healthcare Materials · 2024-02-08 · 23 citations

Skeletal muscle injuries including volumetric muscle loss (VML) lead to excessive tissue scarring and permanent functional disability. Despite its high prevalence, there is currently no effective treatment for VML. Bioengineering interventions such as biomaterials that fill the VML defect to support cell and tissue growth are a promising therapeutic strategy. However, traditional biomaterials developed for this purpose lack the pore features needed to support cell infiltration. The present study…

Ligand-Mediated Targeting of Cytokine Interleukin-27 Enhances Its Bioactivity In Vivo

Molecular Therapy — Methods & Clinical Development · 2020-03-30 · 22 citations

and how the targeting enhances bioactivity of the IL-27 cytokine. We applied the IL-27 gene delivery protocol utilizing sonoporation (sonodelivery) with the goal of reducing prostate tumor growth in an immunocompetent TC2R C57/BL6 model. The reduction in tumor growth and effector cellular profiles implicate targeted IL-27 as more effective than an untargeted version of IL-27 in promoting bioactivity, as assessed by STAT1 and IFN-γ reporter genes. Moreover, enhanced antitumor effects and signific…

IL-27-engineered CAR.19-NK-92 cells exhibit enhanced therapeutic efficacy

Cytotherapy · 2024-06-06 · 13 citations